Skip to main content

Table 2 Patient characteristics and clinical outcomes to post-axitinib systemic therapy

From: Response to post-axitinib treatment in patients with metastatic renal cell carcinoma

Factor   First post-axitinib therapy (n = 25) Second post-axitinib therapy (n = 12)
Interval from End of Axitinib Therapy to Start of Current Therapy Median in weeks (range)   2.0 (0–41.7)a 37.4 (2.6–93.0)
Treatment   N ( %) N ( %)
 VEGF inhibitors   18 (72 %) 3 (25 %)
 Sunitinib   8 (32 %) −0-
 Pazopanib   6 (24 %) 1 (8 %)
 Bevacizumab   4 (16 %) 2 (17 %)
 mTOR inhibitors   7 (28 %) 8 (67 %)
 Everolimus   5 (20 %) 5 (42 %)
 Temsirolimus   2 (8 %) 3 (25 %)
 Other   −0- 1 (8 %)b
ECOG PS    
 0   3 (13 %) 2 (17 %)
 1   19 (79 %) 9 (75 %)
 2   2 (8 %)a 1 (8 %)
Heng Risk Group    
 Favorable   9 (41 %) 3 (30 %)
 Intermediate   12 (55 %) 6 (60 %)
 Unfavorable   1 (5 %)c 1 (10 %)d
Best Response    
 PD   2 (8 %) −0-
 SD   13 (42 %) 6 (55 %)
 PD   7 (28 %) 4 (36 %)
 Not evaluable   3 (12 %) 1 (9 %)a
Reason Treatment Stopped    
 PD/Death   17 (68 %) 6 (54 %)
 Toxicity   4 (16 %) 2 (18 %)
Treatment ongoing   4 (16 %) 3 (27 %)
Duration of Treatment (subsequent therapy) Median in months (range)   4.4 (0.2–27.5+)a 4.8 (0.7–19.1+)a
  1. amissing for one patient
  2. bMK2206
  3. cmissing for three patients
  4. dmissing for two patients